Expérimentation préclinique et recherche clinique
Expérimentation préclinique et recherche clinique
Contact
Arronax Nantes > Expérimentation préclinique et recherche clinique > Nos Publications > Article > 2023

Expérimentation préclinique et recherche clinique

  • Validation of the ΔSUVmax for interim PET interpretation in diffuse large B-cell lymphoma on the basis of the GAINED clinical study. Itti E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, Kraeber-Bodéré F, Meignan M, Gat E, Le Gouill S, Casasnovas RO, Bodet-Milin C. J Nucl Med. 2023, 64: 1706-1711. https://doi.org/10.2967/jnumed.123.265871

  • Multiple myeloma mimicking metastatic skull base paraganglioma in [68 Ga]Ga-DOTATOC-PET/CT and 2-[18F]FDG-PET/CT imaging. Jamet B, Bodet-Milin C, Moreau P, Touzeau C, Kraeber-Bodéré F. Eur J Nucl Med Mol Imaging. 2023, 3792-3793. https://doi.org/10.1007/s00259-023-06322-0

  • New developments in myeloma treatment and response assessment. Kraeber-Bodéré F, Jamet B, Bezzi D, Zamagni E, Moreau P, Nanni C. J Nucl Med. 2023, 64: 1331-1343. https://doi.org/10.2967/jnumed.122.264972

  • PSMA is not specific to prostate cancer. Ah-Thiane L, Ferrer L, Rousseau C. J Nucl Med. 2023, 64: 1326. https://doi.org/10.2967/jnumed.123.265720

  • 2-[18F]FDG PET/CT Flare-up Phenomena Following T-Cell Engager Bispecific Antibody in Multiple Myeloma. Jamet B, Bodet-Milin C, Moreau P, Kraeber-Bodéré F, Touzeau C. Clin Nucl Med. 2023, 48: e230-e231. https://doi.org/10.1097/rlu.0000000000004588

  • Radioimmunotherapy of non-Hodgkin B-cell Lymphoma: an update. Cicone F, Santo G, Bodet-Milin C, Cascini GL, Kraeber-Bodere F, Stokke C, Kolstad A. Semin Nucl Med. 2023, 53: 413-425. https://doi.org/10.1053/j.semnuclmed.2022.12.006

  • Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy. Metz R, Rauscher A, Vaugier L, Supiot S, Drouet F, Campion L, Rousseau C. Cancers. 2023, 15: 1898. https://doi.org/10.3390/cancers15061898

  • Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study. Kraeber-Bodéré F, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Itti E, Karlin L, Bailly C, Levin M-D, Minnema MC, Jamet B, Bodet-Milin C, de Keizer B, Béné MC, Avet-Loiseau H, Sonneveld P, Pei L, Rigat F, de Boer C, Vermeulen J, Kampfenkel T, Lambert J, Moreau P. Haematologica. 2023, 108: 621-626.
    https://doi.org/10.3324/haematol.2021.280051

  • Clinical advances and perspectives in targeted radionuclide therapy. Lepareur N., Ramée B., Mougin-Degraef M., Bourgeois M. Pharmaceutics 2023; 15(6). https://doi.org/10.3390/pharmaceutics15061733

  • Prospective multicentric assessment of 68Ga-DOTANOC PET/CT in grade 1-2 GEP-NET. Lugat A., Frampas E., Touchefeu Y., Mirallie E., Lebras M., Senellart H., Rauscher A., Fleury V., Campion L., Rhomer V., Couturier O., Lebtahi R., Rouzet F., Ruszniewski P., Bodere F., Bourgeois M., Ansquer C. Cancers 2023 15(2), 513. https://doi.org/10.3390/cancers15020513

voir plus de résultats